Vraylar, known generically as cariprazine, has multiple National Drug Code (NDC) codes. These codes are unique identifiers for drug products in the United States, indicating the manufacturer, drug formulation, and package size.
Understanding Vraylar's NDC Codes
The National Drug Code (NDC) system is a universal product identifier for human drugs, maintained by the Food and Drug Administration (FDA). Each code is a unique, 10-digit, 3-segment number. For Vraylar, different strengths or package configurations are assigned distinct NDC codes, all manufactured by Allergan, Inc.
Here is a comprehensive list of NDC codes associated with Vraylar:
| NDC Code | Trade Name | Labeler Name |
|---|---|---|
| 61874-0115 | Vraylar | Allergan, Inc. |
| 61874-0130 | Vraylar | Allergan, Inc. |
| 61874-0145 | Vraylar | Allergan, Inc. |
| 61874-0160 | Vraylar | Allergan, Inc. |
These specific codes help in accurately identifying the particular Vraylar product for prescription, dispensing, and billing purposes. They distinguish different dosage strengths or package sizes of the medication. For example, a different NDC code typically corresponds to a different milligram strength (e.g., 1.5 mg, 3 mg, 4.5 mg, 6 mg) or package quantity of Vraylar.
Why Are NDC Codes Important?
NDC codes serve several critical functions within the healthcare system:
- Drug Identification: They provide a standardized way to identify specific drug products.
- Inventory Management: Pharmacies and distributors use NDCs for efficient tracking and management of drug inventories.
- Reimbursement: Insurance companies and government programs rely on NDC codes for accurate claims processing and reimbursement.
- Patient Safety: They help in reducing medication errors by ensuring the correct drug and dosage are dispensed.
- Regulatory Compliance: The FDA uses NDC data to monitor the drug supply and ensure compliance with regulations.
By understanding the NDC codes for Vraylar, healthcare professionals and patients can ensure proper medication management and dispensing.
